BIP
CRSP icon

Bouvel Investment Partners’s CRISPR Therapeutics CRSP Stock Holding History

Bouvel Investment Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.77M Sell
32,466
-53
-0.2% -$2.79K 0.4% 67
2026
Q1 		$1.55M Buy
32,519
+929
+3% +$49K 0.45% 60
2025
Q4 		$1.66M Sell
31,590
-157
-0.5% -$9.4K 0.48% 62
2025
Q3 		$2.06M Buy
31,747
+586
+2% +$33.6K 0.63% 58
2025
Q2 		$1.52M Buy
31,161
+9,458
+44% +$366K 0.51% 59
2025
Q1 		$1.02M Sell
21,703
-143
-0.7% -$6.06K 0.38% 64
2024
Q4 		$860K Buy
21,846
+143
+0.7% +$6.75K 0.31% 69
2024
Q3 		$1.02M Sell
21,703
-229
-1% -$11.6K 0.38% 64
2024
Q2 		$1.18M Buy
21,932
+4
+0% +$231 0.46% 59
2024
Q1 		$1.49M Buy
21,928
+80
+0.4% +$5.73K 0.65% 54
2023
Q4 		$1.37M Buy
21,848
+942
+5% +$52.1K 0.64% 58
2023
Q3 		$949K Buy
20,906
+391
+2% +$20.2K 0.51% 62
2023
Q2 		$1.15M Buy
20,515
+558
+3% +$31.7K 0.63% 56
2023
Q1 		$903K Buy
19,957
+569
+3% +$27.6K 0.53% 58
2022
Q4 		$788K Buy
19,388
+662
+4% +$35.1K 0.51% 58
2022
Q3 		$1.22M Buy
18,726
+190
+1% +$13.8K 0.82% 48
2022
Q2 		$1.13M Buy
18,536
+226
+1% +$13.3K 0.85% 48
2022
Q1 		$1.15M Buy
18,310
+145
+0.8% +$9.11K 0.7% 54
2021
Q4 		$1.38M Sell
18,165
-214
-1% -$18.7K 0.77% 57
2021
Q3 		$2.06M Sell
18,379
-328
-2% -$41.2K 1.16% 41
2021
Q2 		$3.03M Buy
18,707
+20
+0.1% +$2.43K 1.71% 25
2021
Q1 		$2.28M Sell
18,687
-103
-0.5% -$15.6K 1.46% 32
2020
Q4 		$2.88M Buy
+18,790
New +$2.22M 2.04% 18

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bouvel Investment Partners's CRSP Position: Q2 2026 in Review

Bouvel Investment Partners reduced its CRISPR Therapeutics (CRSP) stake by 0.16% in Q2 2026, selling an estimated $2.79K and leaving 32,466 shares worth $1.77M. The position accounts for 0.4% of the portfolio, ranked #67.

Bouvel Investment Partners first reported a position in CRSP in Q4 2020 and has held it in 23 quarters since. The position peaked at $3.03M in Q2 2021. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Bouvel Investment Partners held 32,466 shares of CRISPR Therapeutics worth $1.77M as of Q2 2026.
  • Bouvel Investment Partners sold 53 CRISPR Therapeutics shares in Q2 2026, an estimated $2.79K.
  • CRISPR Therapeutics made up 0.4% of Bouvel Investment Partners's portfolio in Q2 2026, its #67 holding.
  • Bouvel Investment Partners first reported a position in CRISPR Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Bouvel Investment Partners's CRISPR Therapeutics position peaked at $3.03M in Q2 2021.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Bouvel Investment Partners's 13F filing for Q2 2026, filed 17 Jul 2026.